BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 10100715)

  • 1. Mechanisms of methotrexate resistance in osteosarcoma.
    Guo W; Healey JH; Meyers PA; Ladanyi M; Huvos AG; Bertino JR; Gorlick R
    Clin Cancer Res; 1999 Mar; 5(3):621-7. PubMed ID: 10100715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
    Patiño-García A; Zalacaín M; Marrodán L; San-Julián M; Sierrasesúmaga L
    J Pediatr; 2009 May; 154(5):688-93. PubMed ID: 19159907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells.
    Serra M; Reverter-Branchat G; Maurici D; Benini S; Shen JN; Chano T; Hattinger CM; Manara MC; Pasello M; Scotlandi K; Picci P
    Ann Oncol; 2004 Jan; 15(1):151-60. PubMed ID: 14679136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma.
    Sowers R; Toguchida J; Qin J; Meyers PA; Healey JH; Huvos A; Banerjee D; Bertino JR; Gorlick R
    Mol Cancer Ther; 2003 Jun; 2(6):535-41. PubMed ID: 12813132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity.
    Ifergan I; Meller I; Issakov J; Assaraf YG
    Cancer; 2003 Nov; 98(9):1958-66. PubMed ID: 14584080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Primary study on establishment of namalwa 12/MTX resistant cell strain and its mechanism].
    Chen J; Gu LJ; Ying DM; Shen M; Wu HJ
    Ai Zheng; 2002 Dec; 21(12):1335-40. PubMed ID: 12520743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia.
    Kaufman Y; Drori S; Cole PD; Kamen BA; Sirota J; Ifergan I; Arush MW; Elhasid R; Sahar D; Kaspers GJ; Jansen G; Matherly LH; Rechavi G; Toren A; Assaraf YG
    Cancer; 2004 Feb; 100(4):773-82. PubMed ID: 14770434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study.
    Levy AS; Sather HN; Steinherz PG; Sowers R; La M; Moscow JA; Gaynon PS; Uckun FM; Bertino JR; Gorlick R;
    J Pediatr Hematol Oncol; 2003 Sep; 25(9):688-95. PubMed ID: 12972803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques.
    Hattinger CM; Reverter-Branchat G; Remondini D; Castellani GC; Benini S; Pasello M; Manara MC; Scotlandi K; Picci P; Serra M
    Eur J Cell Biol; 2003 Sep; 82(9):483-93. PubMed ID: 14582536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of resistance to antifolates, a review.
    Banerjee D; Ercikan-Abali E; Waltham M; Schnieders B; Hochhauser D; Li WW; Fan J; Gorlick R; Goker E; Bertino JR
    Acta Biochim Pol; 1995; 42(4):457-64. PubMed ID: 8852336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples.
    Yang R; Sowers R; Mazza B; Healey JH; Huvos A; Grier H; Bernstein M; Beardsley GP; Krailo MD; Devidas M; Bertino JR; Meyers PA; Gorlick R
    Clin Cancer Res; 2003 Feb; 9(2):837-44. PubMed ID: 12576457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance mechanisms to methotrexate in tumors.
    Bertino JR; Göker E; Gorlick R; Li WW; Banerjee D
    Stem Cells; 1996 Jan; 14(1):5-9. PubMed ID: 8820944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene.
    Takebe N; Zhao SC; Adhikari D; Mineishi S; Sadelain M; Hilton J; Colvin M; Banerjee D; Bertino JR
    Mol Ther; 2001 Jan; 3(1):88-96. PubMed ID: 11162315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis.
    Fotoohi AK; Assaraf YG; Moshfegh A; Hashemi J; Jansen G; Peters GJ; Larsson C; Albertioni F
    Biochem Pharmacol; 2009 Apr; 77(8):1410-7. PubMed ID: 19426680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.
    Mintz MB; Sowers R; Brown KM; Hilmer SC; Mazza B; Huvos AG; Meyers PA; Lafleur B; McDonough WS; Henry MM; Ramsey KE; Antonescu CR; Chen W; Healey JH; Daluski A; Berens ME; Macdonald TJ; Gorlick R; Stephan DA
    Cancer Res; 2005 Mar; 65(5):1748-54. PubMed ID: 15753370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of deletions and translocation of the reduced folate carrier gene with profound loss of gene expression in methotrexate-resistant K562 human erythroleukemia cells.
    Ding BC; Witt TL; Hukku B; Heng H; Zhang L; Matherly LH
    Biochem Pharmacol; 2001 Mar; 61(6):665-75. PubMed ID: 11266651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate.
    Yang R; Kolb EA; Qin J; Chou A; Sowers R; Hoang B; Healey JH; Huvos AG; Meyers PA; Gorlick R
    Clin Cancer Res; 2007 May; 13(9):2557-67. PubMed ID: 17473184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Ge Y; Haska CL; LaFiura K; Devidas M; Linda SB; Liu M; Thomas R; Taub JW; Matherly LH
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):451-7. PubMed ID: 17255265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-resistant dihydrofolate reductases: generation, expression and therapeutic application.
    McIvor RS
    Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S50-4. PubMed ID: 8971409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of reduced folate carrier gene (RFC1) expression after exposure to methotrexate in ZR-75-1 breast cancer cells.
    Ma D; Huang H; Moscow JA
    Biochem Biophys Res Commun; 2000 Dec; 279(3):891-7. PubMed ID: 11162445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.